These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36941537)

  • 41. ComPAS: A Bayesian drug combination platform trial design with adaptive shrinkage.
    Tang R; Shen J; Yuan Y
    Stat Med; 2019 Mar; 38(7):1120-1134. PubMed ID: 30419609
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Adaptive Bayesian information borrowing methods for finding and optimizing subgroup-specific doses.
    Zhang J; Lin R; Chen X; Yan F
    Clin Trials; 2024 Jun; 21(3):308-321. PubMed ID: 38243401
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leveraging machine learning: Covariate-adjusted Bayesian adaptive randomization and subgroup discovery in multi-arm survival trials.
    Xiong W; Roy J; Liu H; Hu L
    Contemp Clin Trials; 2024 Jul; 142():107547. PubMed ID: 38688389
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A Bayesian dose-finding trial with adaptive dose expansion to flexibly assess efficacy and safety of an investigational drug.
    Berry SM; Spinelli W; Littman GS; Liang JZ; Fardipour P; Berry DA; Lewis RJ; Krams M
    Clin Trials; 2010 Apr; 7(2):121-35. PubMed ID: 20338905
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability.
    Fujikawa K; Teramukai S; Yokota I; Daimon T
    Biom J; 2020 Mar; 62(2):330-338. PubMed ID: 31608505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A conditional error function approach for adaptive enrichment designs with continuous endpoints.
    Placzek M; Friede T
    Stat Med; 2019 Jul; 38(17):3105-3122. PubMed ID: 31066093
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biomarker-Stratified Phase III Clinical Trials: Enhancement with a Subgroup-Focused Sequential Design.
    Matsui S; Crowley J
    Clin Cancer Res; 2018 Mar; 24(5):994-1001. PubMed ID: 28887317
    [TBL] [Abstract][Full Text] [Related]  

  • 48. BIPSE: A biomarker-based phase I/II design for immunotherapy trials with progression-free survival endpoint.
    Guo B; Zang Y
    Stat Med; 2022 Mar; 41(7):1205-1224. PubMed ID: 34821409
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bayesian adaptive trial design for a continuous biomarker with possibly nonlinear or nonmonotone prognostic or predictive effects.
    Liu Y; Kairalla JA; Renfro LA
    Biometrics; 2022 Dec; 78(4):1441-1453. PubMed ID: 34415052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Flexible Bayesian subgroup analysis in early and confirmatory trials.
    Bunn V; Liu R; Lin J; Lin J
    Contemp Clin Trials; 2020 Nov; 98():106149. PubMed ID: 32942055
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Using Bayesian modeling in frequentist adaptive enrichment designs.
    Simon N; Simon R
    Biostatistics; 2018 Jan; 19(1):27-41. PubMed ID: 28520893
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bayesian hierarchical classification and information sharing for clinical trials with subgroups and binary outcomes.
    Chen N; Lee JJ
    Biom J; 2019 Sep; 61(5):1219-1231. PubMed ID: 30506747
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bayesian response-adaptive designs for basket trials.
    Ventz S; Barry WT; Parmigiani G; Trippa L
    Biometrics; 2017 Sep; 73(3):905-915. PubMed ID: 28211944
    [TBL] [Abstract][Full Text] [Related]  

  • 54. An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment.
    Wu L; Lin J
    J Biopharm Stat; 2024 Apr; ():1-15. PubMed ID: 38651758
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methods for identification and confirmation of targeted subgroups in clinical trials: A systematic review.
    Ondra T; Dmitrienko A; Friede T; Graf A; Miller F; Stallard N; Posch M
    J Biopharm Stat; 2016; 26(1):99-119. PubMed ID: 26378339
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bayesian group sequential enrichment designs based on adaptive regression of response and survival time on baseline biomarkers.
    Park Y; Liu S; Thall PF; Yuan Y
    Biometrics; 2022 Mar; 78(1):60-71. PubMed ID: 33438761
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A promising subgroup identification method based on a genetic algorithm for censored survival data.
    Zhao L; Zhang W; Wu Y; Cao L; Wang L; Li K
    J Biopharm Stat; 2024 Jan; 34(1):55-77. PubMed ID: 36727221
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Treatment evaluation for a data-driven subgroup in adaptive enrichment designs of clinical trials.
    Zhang Z; Chen R; Soon G; Zhang H
    Stat Med; 2018 Jan; 37(1):1-11. PubMed ID: 28948633
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Optimal Bayesian hierarchical model to accelerate the development of tissue-agnostic drugs and basket trials.
    Jiang L; Nie L; Yan F; Yuan Y
    Contemp Clin Trials; 2021 Aug; 107():106460. PubMed ID: 34098036
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.